IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The aim of IMPROVE is to define the optimal maintenance therapy for ANCA-associated
vasculitides (AASV) by comparing the AZA (standard regimen) with MMF in terms of efficacy,
i.e. in preventing relapses.
HYPOTHESIS :
MMF might be more effective than azathioprine as maintenance drug in AASV patients, reducing
by 50% relapse rate, with a same frequency of adverse effects